PARSIPPANY, N.J., Oct. 21, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) approved its Androderm® (testosterone ...
The FDA has approved two lower-dose formulations for Androderm, a once-daily transdermal patch for men with low testosterone. Androderm is manufactured by Watson Pharmaceuticals, Inc. in Corona, Calif ...
The FDA has approved Androderm (testosterone transdermal system; Watson) in 2mg and 4mg formulations. The smaller-sized and lower-dose patch reflects a 20% reduction in the active ingredient from the ...
PARSIPPANY, N.J. — The Food and Drug Administration has approved a new formulation of a testosterone therapy made by Watson Pharmaceuticals, the drug maker said Friday. Watson announced the approval ...
October 21, 2011 — The US Food and Drug Administration (FDA) has approved 2 lower-dose formulations of Watson Pharmaceutical's Androderm (testosterone transdermal system), the company announced today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results